Volume 31, Issue 1 (spring 2007)
Research in Medicine 2007, 31(1): 99-101 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghadiani M, Rahimi H, Rezvani H, Attarian H. Primary plasma cell leukemia: effective treatment with intermediate dose Melphalan. Research in Medicine 2007; 31 (1) :99-101
URL: http://pejouhesh.sbmu.ac.ir/article-1-371-en.html
URL: http://pejouhesh.sbmu.ac.ir/article-1-371-en.html
, mghadiany@taleghanihospital.ir
Abstract: (12623 Views)
Primary Plasma cell Leukemia (PCL) is a rare disease with no standard treatment, although, combination chemotherapy, BMT and intermediate dose melphalan have been shown to be effective, in some case reports. Patients usually present with anemia, thrombocytopenia, hypercalcemia, and renal failure. Diagnosis is confirmed by peripheral and bone marrow examination. We recently had a case in our department. A 43 years old gentleman presented with history of fatigue, weakness, weight loss, dyspnea and bone pain. Diagnosis of PCL was confirmed by PBS and bone marrow exam. The patient was treated using single intermediate dose melphalan (60 mg/m2/ IV) plus Dexamethasone with G–CSF support after 3 weeks, complete remission was achieved.
In the last visit, done 9 months after treatment, he was doing well clinically and his Lab data were normal. This case report confirmed the efficacy of intermediate dose of melphalan in the management of plasma cell leukemia.
Type of Study: Case report |
Received: 2007/12/9 | Published: 2007/04/15
Received: 2007/12/9 | Published: 2007/04/15
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This Journal is licensed under a Creative Commons Attribution 4.0 International License | Research in Medicine
Designed & Developed by : Yektaweb